ChemoCentryx, Inc. (NASDAQ:CCXI) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a note issued to investors on Thursday.

A number of other research analysts have also weighed in on the stock. Zacks Investment Research raised shares of ChemoCentryx from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research note on Monday, July 17th. Cowen and Company reissued a “hold” rating on shares of ChemoCentryx in a research note on Tuesday.

ChemoCentryx (NASDAQ CCXI) traded down 2.484% on Thursday, reaching $7.655. The company’s stock had a trading volume of 48,463 shares. ChemoCentryx has a 12-month low of $3.95 and a 12-month high of $10.80. The company’s 50 day moving average price is $9.63 and its 200-day moving average price is $7.72. The stock’s market cap is $368.61 million.

ChemoCentryx (NASDAQ:CCXI) last issued its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.14. The company had revenue of $8.23 million for the quarter. On average, equities analysts expect that ChemoCentryx will post ($0.90) EPS for the current year.

WARNING: This article was first published by Daily Political and is the property of of Daily Political. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/08/10/chemocentryx-inc-nasdaqccxi-downgraded-to-buy-at-bidaskclub.html.

In related news, insider Petrus Bekker sold 30,000 shares of ChemoCentryx stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $9.98, for a total value of $299,400.00. Following the completion of the sale, the insider now owns 65,963 shares in the company, valued at approximately $658,310.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 223,649 shares of company stock valued at $2,157,360 in the last quarter. 26.80% of the stock is owned by insiders.

A number of hedge funds have recently bought and sold shares of CCXI. Bank of Montreal Can bought a new stake in ChemoCentryx during the second quarter valued at $102,000. JPMorgan Chase & Co. bought a new stake in ChemoCentryx during the second quarter valued at $104,000. Trexquant Investment LP increased its stake in ChemoCentryx by 81.1% in the second quarter. Trexquant Investment LP now owns 18,600 shares of the biopharmaceutical company’s stock valued at $174,000 after buying an additional 8,327 shares during the period. State of Wisconsin Investment Board bought a new stake in ChemoCentryx during the second quarter valued at $178,000. Finally, First Quadrant L P CA bought a new stake in ChemoCentryx during the second quarter valued at $219,000. Hedge funds and other institutional investors own 49.57% of the company’s stock.

ChemoCentryx Company Profile

ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.

Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.